UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2022

SAB BIOTHERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-39871 (Commission File Number) 85-3899721 (IRS Employer Identification No.)

2100 East 54th Street North Sioux Falls, South Dakota (Address of Principal Executive Offices)

exercise price of \$11.50 per share

57104 (Zip Code)

Registrant's Telephone Number, Including Area Code: 605 679-6980

	(Former Name or Former Address, if Changed Since Last Report)				
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:					
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				

Trading				
Title of each class	Symbol(s)	Name of each exchange on which registered		
Common stock, \$0.0001 par value per share	SABS	The NASDAQ Stock Market LLC		
Warrants, each exercisable for one share of Common Stock at an	SABSW	The NASDAQ Stock Market LLC		

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Securities registered pursuant to Section 12(b) of the Act:

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure.

On September 30, 2022, SAB Biotherapeutics, Inc. (the "Company" or "SAB") will conduct a poster presentation at the CRI-ENCI-AACR International Cancer Immunotherapy Conference being held in New York, NY from September 28 to October 1, 2022. The Company will present data on its oncology discovery program regarding how Human anti-human Epidermal Growth Factor Receptor polyclonal antibodies block ligand binding and increase survival of non-small cell lung carcinoma xenograft mice. A copy of the poster presentation is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The foregoing (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act. The information contained in each presentation is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission (the "Commission") and other public announcements the Company may make by press release or otherwise from time to time.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this current report and the presentations that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including the development and efficacy of the Company's influenza program, C. diff. program, Type 1 Diabetes program, and other discovery programs, the likelihood that a patent will issue from any patent application, the results, including timing, of the development of SAB-195 (including any IND filing or proposed clinical trials), financial projections and future financial and operating results (including estimated cost savings and cash runway), the outcome of and potential future government and other third-party collaborations or funded programs (including negotiations with the DoD). These statements are based on the current expectations of the Company and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond the Company's control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause the Company's or the industry's results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further desc

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Poster Presentation dated September 30, 2022
104	Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SAB Biotherapeutics, Inc.

Date: September 30, 2022

/s/ Eddie J. Sullivan

Eddie J. Sullivan Chief Executive Officer

Human Anti-Human Epidermal Growth Factor Receptor Polyclonal Antibodies Block Ligand Binding and Increase Survival of Non-small Cell Lung Carcinoma Xenograft Mice

Daniel W. Vermeer, Paul L. Colbert, Tom C. Luke, Hua Wu, Christoph L. Bausch and Kristi A. Egland **BIOTHERAPEUTICS** SAB Biotherapeutics, Sioux Falls, SD

Abstract

Background

1. DiversitAb™ Development Process for generation of human anti-human EGFR polyclonal antibodies, SAB-162E




Figure 1. Generation of human anti-human EGFR polyclonal antibodies (SAB-162E) using the DiversitAhTM platform.




Figure 2. SAB-162E binding to EGFR and EGFRvIII.

Results

3. SAB-162E blocks EGF- EGFR binding and downstream signaling.




Figure 3. SAB-162E blockade of EGF- EGFR binding and

5. SAB-162E inhibits cellular

igure 5. Effect of SAB-162E on

n

migration of NSCLC cells.

4. SAB-162E decreases cellular proliferation.




Figure 4. Effect of SAB-162E on cellular proliferation


- dependant manner. Treatment of a MODSCID master CDX H292 model with SAII-162E indicated a dose responsive offset on lumer volume. The highest dose significantly silved lumes growth and tripied sorvival time. Filesis—ticks history pAR thrapparises could have distinct advantages over monocloted antibodies, such as trageling cancer types with high maniformal hundra or cancer with matiple; tragest. The DosestiAb platform is a powerful sort to generate targeted fusion pARs against a variety of tumo-cassistical subjects, such as CD20, EGFRsIII and Her-2, for the treatment of complex human cancers.

Acknowledgements

6. SAB-162E activates ADCC and CDC effector

10.74

Figure 6. Activation of ADCC and CDC by SAB-162E



7. SAB-162E decreased mouse in vivo tumor

growth and almost tripled survival time.

Conclusions